Travere Therapeutics (TVTX) is back in focus after the FDA extended its review of the company’s supplemental filing for FILSPARI in focal segmental glomerulosclerosis, following new data submissions to better clarify clinical benefit.

The FDA review extension lands after a choppy few months for Travere’s share price. A 7 day share price return of 5.63% is set against a 30 day share price return decline of 25.73% and a 1 year total shareholder return of 44.95%. This suggests that longer term holders have still seen gains even as near term momentum has cooled.

If this kind of regulatory catalyst has your attention, it could be a useful time to scan other healthcare stocks that might be reacting to similar clinical or approval milestones.

With Travere shares recently closing at US$29.44 and trading at a reported discount to both analyst targets and some intrinsic value estimates, you have to ask: is this regulatory delay creating a buying window, or is the market already pricing in future growth?

Most Popular Narrative: 29.3% Undervalued

Travere’s most followed narrative puts fair value at about $41.64 per share versus the recent $29.44 close, framing the current FDA delay against a still optimistic long term picture.

Expansion of FILSPARI's label to include treatment for FSGS, a rare kidney disease with no approved therapies, positions Travere for first-mover advantage in a large, underserved market. If approved, this will create a new, high-margin revenue stream and significantly expand the company's addressable market.

Curious what earnings trajectory and margin shift justify that kind of gap to fair value? The narrative leans heavily on rapid revenue expansion and a richer profit profile. The assumptions behind that are detailed, and they are not shy. If you want to see exactly how those moving parts add up to the $41.64 figure, the full story lays it all out.

Result: Fair Value of $41.64 (UNDERVALUED)

However, the whole story hinges on FILSPARI, so any regulatory setback in FSGS or slower uptake in IgA nephropathy could quickly challenge that undervaluation thesis.

Another Angle On Value

So far the story leans on cash flow driven fair value and a 29.3% discount to the US$41.64 narrative estimate. If you look instead at the current P/S of 6x versus a peer average of 3.5x and a fair ratio of 5.7x, TVTX suddenly looks richer, not cheaper. Is this a cushion or a warning sign?

Build Your Own Travere Therapeutics Narrative

If you are not sold on these assumptions or prefer to weigh the data yourself, you can build a custom Travere view in minutes with Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Travere Therapeutics.

Looking for more investment ideas?

If Travere has you thinking more broadly about opportunities, do not stop here. You will miss plenty of potential ideas if you only follow one story.

• Spot early opportunities by checking out these 3523 penny stocks with strong financials that already pair stronger fundamentals with more disciplined balance sheets.
• Ride the AI trend with these 23 AI penny stocks that tie artificial intelligence to real products, customers, and tangible revenue.
• Zero in on pricing gaps using these 874 undervalued stocks based on cash flows that appear cheap based on cash flow expectations, before the wider market catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.